XTL BiopharmaceuticalsXTLB
13F holders, Q1 2025 (March 31)4holders +1
1new positions
0sold out
1famous investor
$1.20avg. 13F price*
At the end of Q1 2025, 4 institutions reported holding XTL Biopharmaceuticals Ltd. (XTLB) in their 13F filings, up 1 from Q4 2024. 1 opened new positions and 0 sold out. The largest holders were Noked Israel Ltd ($238K), Citadel Advisors ($31K) and Morgan Stanley ($16K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- XTL Biopharmaceuticals Ltd.
- CUSIP
- 98386D307
- Latest filing quarter
- Q4 2025
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $31K |
| Exits | 0 | $0 |
All 13F filers, Q4 2024 → Q1 2025: 25,211 shares bought and 5,100 shares sold, net +20,111 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Noked Israel Ltd | 0.05% | No change | 198,888 | $238K |
| Citadel Advisors | 0.00% | New | 25,211 | $31K |
| Morgan Stanley | 0.00% | Reduce -27.8% | 13,251 | $16K |
| Rhumbline Advisers | 0.00% | No change | 10,954 | $14K |
"% of holder's portfolio" is XTLB's weight in each manager's 13F, not the share of XTL Biopharmaceuticals Ltd. the manager owns.